Navigation Links
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
Date:6/30/2011

0

648Patients enrolled in extension studies (n=643)

1,080

648

432Patients successfully treated and enrolled in extension study (n=478)

623

451

172Joints with recurrence at 1 year (n/%)

19/623 (3.0%)

8/451 (1.8%)

11/172 (6.4%)Joints with recurrence at 2 years (n/%)

122/623(19.6%)

64/451(14.2%)

58/172(33.7%)Joints with recurrence at 3 years (n/%)

217/623 (34.8%)

120/451 (26.6%)

97/172 (56.4%)The study also tracks whether a joint successfully treated with XIAFLEX received any further medical intervention.  Through year three of follow-up 93.1% of joints that were successfully treated with XIAFLEX did not receive any medical or surgical intervention. Of the 43 (6.9 %) successfully treated joints that received medical or surgical intervention through three years, 30 had surgery, seven received needle aponeurotomy (of which 2 subsequently received a third intervention), and six received XIAFLEX.  XIAFLEX has been commercially available in the U.S. only since March 2010.

Other Top-Line Findings through Three Years:

  • High severity PIP joints (those with baseline contractures > 40 degrees) had a statistically significant higher recurrence rate than low severity PIP joints (71% versus 50%, respectively).  Combined with data from the CORD I study this suggests that treatment of PIP joints, before they reach high severity, may be beneficial(1).
  • Recurrence rates in successfully treated MP joints with low severity (those with baseline contractures less than or equal to 50 degrees) and high severity were not statistically different.
  • Sixteen patients in this study have been retreated with XIAFLEX (6 in a previously successfully treated joint and the remainder in previously untreated joints) through three years follow-up, with a local adverse event profile similar to previous first-line clinical studies.  One ret
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
    5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
    6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
    7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
    8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
    11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
    (Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
    (Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
    Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
    ... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
    ... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
    Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
    (Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its ... signage media player promotion for Dec. 2014. , The ... wave in April, and this promotion will help to expand ... desired models on our website, she/he can contact us with ... new models come in the latest designs, and they actually ...
    (Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) announced ... honor of World AIDS Day 2014. On Nov. 25, ASCP ... icon and infographic designed to generate public awareness about World ... , ASCP has asked members to replace their Facebook, Twitter, ... Tested. Find a cure.” icon and share the accompanying infographic ...
    (Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 ... the 50 fastest-growing technology companies in the UK. Rankings ... years. Cambrionix Ltd grew 2989 percent during this period. ... of Cambridgeshire and East and first in the sector of ... recognition of the hard work put in by our team ...
    (Date:11/27/2014)... York (PRWEB) November 27, 2014 ... have been filed in a consolidated litigation now ... reports. , Documents recently updated in the ... included in the state proceeding, all of which ... disorder and other psychiatric conditions. Many of the ...
    (Date:11/27/2014)... PA (PRWEB) November 27, 2014 In order ... inventor from Sharpes, Fla., designed an easy way to avoid ... it/them. , He then created a prototype of the patent-pending ... or lower a toilet seat and/or lid in a more ... prevents the spread of germs. Overall, it promotes good hygiene ...
    Breaking Medicine News(10 mins):Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4
    ... all think we know a lot about vitamins, minerals ... studies have created confusion regarding their importance; a simple ... is that “Vitamins and other nutrients, including calcium and ... ,Stressing the point is Dr. Joseph C. Maroon, ...
    ... forefront of the mission to translate discoveries in basic sciences ... schools to have been chosen to receive a collective grant ... ,"The gap between basic biology and medical practice is ... education at the School of Medicine and principal investigator of ...
    ... in Russia has been witness to the death of more ... has hit the south of Russia.// ,According to ... Jan 25 and Feb 1, almost 350,000 birds have died ... 76,000 at the Makhachkalinskaya farm between Feb. 6 and Feb. ...
    ... response of MPs in favor of the proposed smoking ban in ... would be imposed by the summer of next year in the ... 184 has been achieved when the issue of smoking ban extension ... Following implementation of the law, both the public and club/pub workers ...
    ... mammalian protein called Rad9 could hold the key to killing ... at Washington University School of Medicine in St. Louis. Rad9 ... DNA, but it is now fund to be a "repairman" ... ,That is why reserachers are now ...
    ... the world's most common liver infection. It spreads easily and ... ,It causes liver cirrhosis, // liver failure and liver ... of the world's population, has been infected with the hepatitis ... are chronic carriers of the virus. Normally in case of ...
    Cached Medicine News:Health News:Never undermine the importance of calcium and Vitamin D 2Health News:Getting Basic Science to Work For Medicine 2Health News:Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer 2
    Classic black cast boot with unisex styling...
    ... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
    The Multi-Purpose Medical-Surgical Shoe...
    The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
    Medicine Products: